Residual or Recurrent Grade 2 IDH Mutant Glioma
1 clinical trials · Condition
◉ Watch Residual or Recurrent Grade 2 IDH Mutant Glioma
| Record | Firm | Date |
|---|---|---|
| Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation (NCT06780930) | Servier | 2024-10-18 |
Track Residual or Recurrent Grade 2 IDH Mutant Glioma automatically
Every clearance here is in the API, with alerts when new ones post.